MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). The purchase price comprises US$33.1 million upfront, which is payable in the form of 4,369,914 Telix ordinary shares to be issued at closing, subject to certain cash adjustments (at or after closing) which…
All posts tagged QSAM Biosciences
Telix Pharmaceuticals to acquire QSAM Biosciences and its bone cancer therapy
MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited, an Australian company that develops radiopharmaceuticals for cancer diagnosis and treatment, has announced its intention to acquire QSAM Biosciences, Inc., a U.S. based clinical stage company that is developing a novel therapy for bone cancer. QSAM’s lead asset, CycloSam®, is a radioactive compound that selectively targets and kills cancer cells…